T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$18.7B |
| 2 |
Apple
AAPL
|
+$5.48B |
| 3 |
NVIDIA
NVDA
|
+$5.33B |
| 4 |
Tesla
TSLA
|
+$4.47B |
| 5 |
Microsoft
MSFT
|
+$2.15B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$4.26B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.3B |
| 3 |
Morgan Stanley
MS
|
+$2.82B |
| 4 |
Global Payments
GPN
|
+$2.43B |
| 5 |
PayPal
PYPL
|
+$2B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.36% |
| 2 | Healthcare | 16.09% |
| 3 | Consumer Discretionary | 15.79% |
| 4 | Communication Services | 12.38% |
| 5 | Financials | 10.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
Devon Energy
DVN
$48.7B
| $653M | 0.06% |
14,816,969
-1,016,057
| -6% | -$42.3M |
|
302
Acadia Healthcare
ACHC
$2.87B
| $649M | 0.06% |
10,688,959
+5,146
| +0% | +$307K |
|
303
ICU Medical
ICUI
$4.54B
| $647M | 0.06% |
2,725,540
+30,030
| +1% | +$7.01M |
|
304
Trex
TREX
$5.07B
| $644M | 0.06% |
4,767,532
+1,998,846
| +72% | +$240M |
|
305
Ascendis Pharma A/S
ASND
$16.2B
| $641M | 0.06% |
4,761,193
-74,521
| -2% | -$11.1M |
|
306
Mercado Libre
MELI
$93.4B
| $636M | 0.06% |
471,464
+19,893
| +4% | +$27.9M |
|
307
SBA Communications
SBAC
$19.8B
| $634M | 0.06% |
1,629,805
+138,542
| +9% | +$48.7M |
|
308
Crown Castle
CCI
$32.4B
| $631M | 0.06% |
3,020,866
-92,669
| -3% | -$17.1M |
|
309
EastGroup Properties
EGP
$11B
| $630M | 0.06% |
2,763,335
+48,484
| +2% | +$9.74M |
|
310
RenaissanceRe
RNR
$13.3B
| $626M | 0.06% |
3,697,314
+251,491
| +7% | +$39.4M |
|
311
Toro Company
TTC
$9.28B
| $624M | 0.06% |
6,246,264
-883,851
| -12% | -$88M |
|
312
Corning
GLW
$141B
| $620M | 0.06% |
16,657,004
-53,733
| -0.3% | -$2.01M |
|
313
Moderna
MRNA
$25.3B
| $618M | 0.06% |
2,431,808
-6,282
| -0.3% | -$1.84M |
|
314
Motorola Solutions
MSI
$76.9B
| $616M | 0.06% |
2,267,471
+1,218,373
| +116% | +$307M |
|
|
SEM
315
DELISTED
Select Medical
SEM
| $615M | 0.06% |
38,847,788
+1,156,383
| +3% | +$19.7M |
|
316
Analog Devices
ADI
$188B
| $615M | 0.06% |
3,499,303
-3,750,810
| -52% | -$665M |
|
317
Aurora
AUR
$13.5B
| $615M | 0.06% |
+56,342,737
| New | +$625M |
|
318
Peloton Interactive
PTON
$2.36B
| $615M | 0.06% |
17,187,776
+13,175,945
| +328% | +$804M |
|
319
Kanzhun
BZ
$6.83B
| $611M | 0.06% |
17,509,979
+7,472,587
| +74% | +$262M |
|
320
Skyworks Solutions
SWKS
$10.5B
| $609M | 0.05% |
3,927,586
-11,424
| -0.3% | -$1.83M |
|
321
Entergy
ETR
$49.9B
| $608M | 0.05% |
10,789,710
+4,999,316
| +86% | +$263M |
|
|
TMX
322
DELISTED
Terminix Global Holdings, Inc.
TMX
| $606M | 0.05% |
13,390,372
-190,610
| -1% | -$7.77M |
|
323
Amgen
AMGN
$226B
| $600M | 0.05% |
2,668,536
+47,146
| +2% | +$9.95M |
|
324
Littelfuse
LFUS
$11.5B
| $596M | 0.05% |
1,894,707
+38,766
| +2% | +$11.7M |
|
325
Verizon
VZ
$199B
| $585M | 0.05% |
11,256,175
-333,734
| -3% | -$17.4M |
|
Similar funds
T. Rowe Price Associates's Q4 2021 Portfolio in Review
As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
- T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
- T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
- T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
- T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
- T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.